HighTower Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HighTower Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,858	Closed	-$509K	–	4050
2025 Q1	$509K	Sell	3,858 -321	-8%	-$40K	﹤0.01%	2444
2024 Q4	$349K	Buy	4,179 +350	+9%	+$28.8K	﹤0.01%	2766
2024 Q3	$280K	Buy	+3,829	New	+$288K	﹤0.01%	2860
2024 Q2	–	Sell	-3,474	Closed	-$238K	–	3963
2024 Q1	$238K	Sell	3,474 -27	-0.8%	-$1.86K	﹤0.01%	2868
2023 Q4	$250K	Buy	+3,501	New	+$201K	﹤0.01%	2845

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HighTower Advisors's ITCI Position: Q2 2025 in Review

HighTower Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,858 shares — an estimated $509K sold.

HighTower Advisors first reported a position in ITCI in Q4 2023 and held it in 5 quarters. The position peaked at $509K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

HighTower Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
HighTower Advisors sold 3,858 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $509K.
HighTower Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 5 quarters.
HighTower Advisors's Intra-Cellular Therapies Inc. position peaked at $509K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.